Document is current
Any future updates will be listed below
-
Authors
Heinolainen, Krista
Saarinen, Silva
Vertuani, Simona
Ellonen, Antti
Karlsson, Antti
Utriainen, Meri
Carlqvist, Peter
Mandelin, Jami
Holm, Barbro http://orcid.org/0000-0002-2944-9464
-
Funding
Funding for this research was provided by:
Novartis Finland
- License Information
-
More Information
Article History
Received: 24 January 2023
Accepted: 22 March 2023
First Online: 13 May 2023
Declarations
:
: KH, SS, SV, and BH are employees of Novartis Finland Oy. PC was a full-time employee of Novartis Sverige AB at the time of the initiation of the study. AK was a full-time employee of Auria Biobank at the time of the initiation of the study. JM is an employee of Faron Pharmaceuticals. AE, MU, and TA have no competing interests.
: The study approval was obtained from the Scientific Steering Committee of Auria Biobank (AB17-3826) and Hospital District of Southwest Finland (T147_208). The study was performed in accordance with the declaration of Helsinki and in compliance with applicable national laws.
: The retrospectively collected tissue samples and related clinical data have been transferred to the Biobank by public announcement and can be used for scientific research purposes without informed consent according to the Finnish Biobank Act (688/2012).
: Not applicable.
